(Q45931497)

17 December 2017

title

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. (English)

1 reference

17 December 2017

0 references

Dieter Naber

1

1 reference

17 December 2017

Martin Lambert

series ordinal

2

1 reference

17 December 2017

publication date

1 August 2009

1 reference

17 December 2017

published in

CNS Drugs

1 reference

17 December 2017

volume

23

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

649-659

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.2165/00023210-200923080-00002

exact match

0 references

cites work

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

1 reference

12 December 2020

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

12 December 2020

Subjective effects of antipsychotic treatment

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

1 reference

12 December 2020

Pharmacotherapy of first-episode schizophrenia

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

1 reference

12 December 2020

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

1 reference

12 December 2020

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

12 December 2020

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

1 reference

12 December 2020

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

12 December 2020

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

12 December 2020

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

1 reference

12 December 2020

A depression rating scale for schizophrenics

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

12 December 2020

Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics

1 reference

12 December 2020

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

12 December 2020

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

12 December 2020

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

12 December 2020

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

12 December 2020

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics

1 reference

12 December 2020

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

12 December 2020

The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.

1 reference

12 December 2020

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

CATIE and CUtLASS: can we handle the truth?

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

1 reference

12 December 2020

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol

1 reference

12 December 2020

Understanding the results of CATIE in the context of the field.

1 reference

12 December 2020

Do effectiveness ("real world") studies on antipsychotics tell us the real truth?

1 reference

12 December 2020

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

1 reference

12 December 2020

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

12 December 2020

Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia

1 reference

12 December 2020

Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia

1 reference

12 December 2020

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

1 reference

12 December 2020

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

12 December 2020

Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.

1 reference

12 December 2020

Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

12 December 2020

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

12 December 2020

Implications of the CATIE trial on treatment: extrapyramidal symptoms

1 reference

12 December 2020

What would the patient choose? Subjective comparison of atypical and typical neuroleptics

1 reference

12 December 2020

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

1 reference

12 December 2020

Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial.

1 reference

12 December 2020

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

1 reference

12 December 2020

10.2165/00023210-200923080-00002

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

1031834578

0 references

1 reference

17 December 2017